z-logo
Premium
Mastocytosis
Author(s) -
Fine JoDavid
Publication year - 1980
Publication title -
international journal of dermatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1980.tb00272.x
Subject(s) - medicine , urticaria pigmentosa , disease , systemic mastocytosis , dermatology , regimen , cutaneous mastocytosis , chemotherapy , puva therapy , surgery , psoriasis
Mastocytosis implies involvement by excessive numbers of mast cells, of skin and/or other organs. Symptoms may be absent to severe, even occasionally life-threatening. H1- and H2-blocking agents potentially may relieve symptoms, but do nothing to prevent systemization. At present no specific combination chemotherapy regimen has been shown to be markedly effective in a large controlled study. Mithramycin may be of benefit in relieving localized bone pain, although confirmation of this observation in large numbers of patients is needed. PUVA may be a viable approach to symptomatic treatment of otherwise poorly controlled urticaria pigmentosa. In children, urticaria pigmentosa is a relatively benign disease without an increased risk of later systemic involvement. In adults, however, other organs by be involved, with resultant increased morbidity and mortality. Without specific symptoms to a particular organ system, elaborate and expensive staging work-up is not indicated, at least until there is evidence that a reproducibly effective therapy for systemic disease exists.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here